NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Dianthus Therapeutics, Inc. DNTH
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.0M
▼ 67.3% vs FY2024
EPS · FY25
$-4.20
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-38.4%
Net margin · FY25
-7973.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.0M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 7973 cents on every revenue dollar this year.
Per share
USD -4.20
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-38.4%
Return on equity, FY2025
ROE
Operating margin-8739.3%
Net margin-7973.3%
Return on assets-35.9%
Each USD of equity lost 38 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 530.9M
total assets, end of FY2025
Total assetsUSD 530.9M
EquityUSD 493.4M
CashUSD 51.1M
Current ratio13.32×
Equity funds 93% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−4.20
−2.55
−8.45
−32.57
−1.29
−1.71
−2.07
−3.13
−19.12
−65.15
Dividend / sh $
0.00
0.00
0.00
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−38.4
−32.6
−70.0
·
−112.3
−52.6
−53.5
−111.1
·
·
Shares out B
0.04
0.03
0.01
0.00
0.06
0.05
0.04
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed